Lannett Company Profile (NYSE:LCI)

Analyst Ratings

Consensus Ratings for Lannett (NYSE:LCI) (?)
Ratings Breakdown: 1 Sell Rating(s), 2 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $30.25 (1.37% downside)

Analysts' Ratings History for Lannett (NYSE:LCI)
Show:
DateFirmActionRatingPrice TargetActions
7/12/2016Oppenheimer Holdings Inc.Reiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2016Deutsche Bank AGInitiated CoverageHold$26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/25/2016SusquehannaLower Price Target$37.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/25/2016Craig HallumLower Price TargetBuy$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/24/2016Roth CapitalLower Price TargetBuy$30.00 -> $27.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/24/2016Canaccord GenuityDowngradeBuy -> Sell$28.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/27/2016Raymond James Financial Inc.Lower Price Target$45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for Lannett (NYSE:LCI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/23/2016        
5/3/2016Q316$0.63$0.75$160.49 million$163.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/3/2016Q216$0.94$0.95$141.62 million$127.06 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2015Q116$0.89$0.99$103.90 million$106.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/25/2015Q415$0.86$0.91$99.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015Q315$0.94$0.97$101.10 million$99.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/4/2015Q215$1.06$1.21$102.95 million$114.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2014Q115$0.79$0.94$91.40 million$93.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/27/2014Q414$0.54$0.64$79.50 million$80.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2014Q314$0.60$0.63$84.50 million$80.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/6/2014Q214$0.39$0.46$62.21 million$67.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2013Q114$0.13$0.22$41.14 million$45.82 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
9/10/2013Q4 2013$0.07$0.12$37.89 million$40.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2013Q3 2013$0.13$0.14$35.14 million$39.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/7/2013Q2 2013$0.05$0.10$33.53 million$36.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/8/2012Q113$0.05$0.07$33.76 million$35.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Lannett (NYSE:LCI)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20165$0.60$0.91$0.77
Q2 20167$0.62$1.10$0.93
Q4 20163$0.60$0.69$0.63
Q1 20171$0.70$0.70$0.70
Q2 20171$0.75$0.75$0.75
Q3 20171$0.80$0.80$0.80
Q4 20171$0.86$0.86$0.86
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Lannett (NYSE:LCI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Lannett (NYSE:LCI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/23/2016Robert EhlingerVPSell37,141$25.06$930,753.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/20/2016Robert EhlingerVPSell62,859$25.40$1,596,618.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/1/2016Robert EhlingerVPSell69,247$25.41$1,759,566.27View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2016Arthur P BedrosianCEOBuy4,500$24.91$112,095.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2016David A DrabikDirectorBuy1,277$24.74$31,592.98View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2016Kevin SmithVPBuy1,500$24.75$37,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2016Martin P GalvanCFOBuy3,000$24.65$73,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015Arthur P BedrosianCEOSell5,000$55.64$278,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015John AbtVPBuy1,000$54.77$54,770.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Arthur P BedrosianCEOSell5,000$52.81$264,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2015Arthur P BedrosianCEOSell5,000$61.92$309,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Arthur P BedrosianCEOSell5,000$56.31$281,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2015Arthur P BedrosianCEOSell5,000$53.27$266,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015Arthur P BedrosianCEOSell5,000$69.43$347,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015Arthur P BedrosianCEOSell5,000$65.23$326,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015William SchreckCOOSell134,635$64.99$8,749,928.65View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2015William SchreckCOOSell50,000$63.35$3,167,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2015David A DrabikDirectorSell12,500$61.55$769,375.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2015Arthur P BedrosianCEOSell5,000$59.89$299,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2015G. Michael LandisInsiderSell11,500$58.60$673,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/13/2015Jeffrey FarberDirectorSell35,000$58.18$2,036,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/11/2015Kevin SmithVPSell109,436$56.51$6,184,228.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/9/2015David FarberMajor ShareholderSell2,500$55.00$137,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/9/2015Kevin SmithVPSell53,534$55.36$2,963,642.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/6/2015G. Michael LandisInsiderSell12,049$52.93$637,753.57View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/26/2015David FarberMajor ShareholderSell7,500$50.00$375,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2015Arthur P BedrosianCEOSell5,000$43.50$217,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2014Arthur P BedrosianCEOSell5,000$43.81$219,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2014Martin P GalvanCFOBuy1,000$42.40$42,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2014Ernest SaboVPSell6,000$48.03$288,180.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/27/2014David FarberMajor ShareholderSell7,500$50.00$375,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2014Arthur P BedrosianCEOSell5,000$40.05$200,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2014David FarberMajor ShareholderSell5,000$41.30$206,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2014Arthur P BedrosianCEOSell5,000$47.19$235,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2014David FarberMajor ShareholderSell7,500$50.00$375,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014Arthur P BedrosianCEOSell5,000$46.96$234,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014David FarberMajor ShareholderSell10,000$43.53$435,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014Paul TaveiraDirectorSell1,000$46.94$46,940.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2014William SchreckCOOSell16,600$43.85$727,910.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/12/2014William SchreckCOOSell55,563$43.31$2,406,433.53View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/20/2014Kevin SmithVPSell64,665$45.11$2,917,038.15View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/13/2014Kevin SmithVPSell20,000$40.48$809,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/13/2013Arthur BedrosianCEOBuy5,000$27.85$139,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/13/2013Martin GalvanCFOBuy3,000$26.90$80,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2013Kevin SmithVPSell24,984$11.86$296,310.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2013Kevin SmithVPSell41,929$11.80$494,762.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/10/2013Ernest SaboVPSell15,000$11.29$169,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2013Paul TaveiraDirectorBuy1,000$9.73$9,730.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/13/2013Martin P GalvanCFOBuy4,000$6.88$27,520.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Lannett (NYSE:LCI)
DateHeadline
07/22/16 04:50 PMLannett Co Inc (LCI) is Trading Higher on Unusual Volume for July 21 - Equities.com
07/22/16 07:53 AMOverview of Analysts Suggestions: AbbVie Inc. (NYSE:ABBV) , Lannett Co Inc (NYSE:LCI) - Street Updates
07/22/16 07:53 AMLannett Co Inc (NYSE:LCI): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/22/16 07:53 AMLannett Company, Inc. (NYSE:LCI) Insiders Look Pessimistic About Prospects - Review Fortune
07/22/16 07:53 AMLannett Co Inc (LCI) Jumps 5.13% on July 20 - Equities.com
07/22/16 07:53 AMTelemus Capital buys $177561222 stake in Lannett Company (LCI) - TheFounders Daily
07/21/16 03:25 PMFracking Sand Among Market Hot Spots -
07/20/16 03:03 PMTwo Buzzers within Analysts Radar: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) , Lannett Co Inc (NYSE:LCI) - Street Updates
07/20/16 03:03 PMAre Analysts Bearish Lannett Company, Inc. (NYSE:LCI) After Last Week? - Consumer Eagle
07/20/16 08:51 AMLannett Gets FDA Acceptable Filing Letter For Fentanyl Patch ANDA -
07/20/16 07:53 AMLannett (LCI) Shares Cross Above 200 DMA
07/20/16 07:53 AMLannett Announces Receipt Of FDA Acceptable Filing Letter For Fentanyl Patch ANDA
07/19/16 05:01 PMLannett Co Inc Common Stock (LCI) Ownership Increased by Telemus Capital, LLC - Finance Daily
07/19/16 11:00 AMShares Lower on the Year Lannett Company, Inc. (NYSE:LCI) - Press Telegraph
07/19/16 11:00 AMLannett Co Inc (NYSE:LCI)'s Growth Projection - RealistInvestor.com
07/19/16 11:00 AMEquity Roundup: Stock Performance Focus on Lannett Co Inc (NYSE:LCI) - Press Telegraph
07/19/16 11:00 AMShares of Lannett Co Inc (LCI) Rally 15.58% - Trade Calls
07/17/16 09:14 AMLannett Co Inc (LCI): Price Target and June Short Interest Disclosure - Trade Calls
07/15/16 09:01 AMLannett Co Inc (NYSE:LCI) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/15/16 09:01 AMMost recent Analysts Rating report: Sanofi (NYSE:SNY) , Lannett Co Inc (NYSE:LCI) - Street Updates
07/15/16 09:01 AMBroker Outlook For Lannett Co Inc (NYSE:LCI) - Fiscal Standard
07/12/16 09:17 AMFDA approves Lannett's Paroxetine Extended Release Tablets
07/12/16 09:17 AMLannett Announces Approval And Launch Of Paroxetine Extended Release Tablets USP, 12.5 Mg, 25 Mg, 37.5 Mg
07/12/16 09:17 AMLannett Co. (LCI) Gets FDA Approval, Stock Soars 10.5%
07/12/16 09:17 AMLannett Co. (LCI) Climbed To A 5-Month High After FDA Approval
07/11/16 04:57 PMStock Volatility Focus for: Lannett Company, Inc. (NYSE:LCI) - Engelwood Daily
07/11/16 04:57 PMLannett Co. (LCI) Gets FDA Approval, Stock Soars 10.5% - Yahoo Finance
07/11/16 03:33 PMWhy Wynn Resorts, Lannett, and Sagent Pharmaceuticals Jumped Today -
07/11/16 09:37 AMStock Performance Rundown on: Lannett Company, Inc. (NYSE:LCI) - Press Telegraph
07/11/16 09:37 AMLannett Co Inc (NYSE:LCI) Receives Update on Growth Forecast - RealistInvestor.com
07/11/16 08:45 AMLannett Gets FDA Approval To Launch Paroxetine Extended Release Tablets - Lannett Company, Inc. (NYSE: LCI) revealed it received FDA approval recently for its Abbreviated New Drug Application (ANDA) for Paroxetine Extended Release Tablets USP, 12.5 mg, 25 mg and 37.5 mg. The company also launched Paroxetine, which is the therapeutic equivalent to the reference listed drug, Paxil CR Extended-Release Tablets USP, 12.5 mg, 25 mg and 37.5 mg, of Apotex Technologies. Lannett quoted IMS to suggest that total sales of Paroxetine ...Full story available on Benzinga.com
07/10/16 09:11 AMNext Weeks Broker Price Targets For Lannett Co Inc (NYSE:LCI) - Fiscal Standard
07/07/16 04:58 PMShort Information Review for: Lannett Company, Inc. (NYSE:LCI) - Engelwood Daily
07/07/16 04:58 PMShares Declining and Worrying Investors: Lannett Company, Inc. (NYSE:LCI) - Telanagana Press
07/07/16 04:58 PMCan Lannett Co Inc (NYSE:LCI) Improve on the Earnings Front? - Engelwood Daily
07/07/16 04:58 PMLannett Co Inc (LCI) : Analyst Rating Update - Trade Calls
07/07/16 07:52 AMChief Scientific Affairs of Lannett Co Inc (NYSE:LCI), Dedhiya Mahendra, buys 1,000 shares worth $24,840
07/06/16 05:09 PMInsiders Selling, Short Interest Growing Lannett Co Inc Common Stock (NYSE:LCI)
07/03/16 04:28 PMLannett Co Inc (NYSE:LCI) Target Price Is $29.875 - RealistInvestor.com
06/30/16 05:12 PMShort Data Recap for: Lannett Company, Inc. (NYSE:LCI) - Engelwood Daily
06/30/16 05:12 PMLannett Co Inc (NYSE:LCI) Earnings Glance and Target Price Review - Engelwood Daily
06/29/16 04:48 PMA Fairly Balanced Risk And Reward Scenario For Lannett; Deutsche Bank Initiates At Hold
06/29/16 07:45 AMLannett Co Inc (NYSE:LCI) Accounts Payable Stands AT $33.038 - RealistInvestor.com
06/28/16 09:47 AMDrugs - Generic Stocks Technical Snapshot - Sophiris Bio, Neurocrine Biosciences, Lannett, and Supernus Pharma
06/28/16 06:11 AMLannett Receives FDA Approval For Diazepam Oral Solution, 5 mg/5 mL - [at noodls] - PHILADELPHIA, June 28, 2016/PRNewswire / -- Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug ...
06/27/16 09:16 AMLannett Co Inc (NYSE:LCI) Broker Price Targets For The Coming Week - Fiscal Standard
06/24/16 07:22 AM3 Healthcare Stocks That Are Looking Cheap -
06/23/16 05:20 PMLannett Co Inc (NYSE:LCI) Current Analyst Ratings - Fiscal Standard
06/23/16 05:20 PMMy Most Bearish Valuation Of Lannett - Seeking Alpha
06/21/16 04:35 PMLannett : Draws Bearish Attention After Forming Double Bottom

Social

About Lannett

Lannett logoLannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company's products include Levothyroxine Sodium tablets, Digoxin tablets, Butalbital products, Ursodiol capsules and pain management products. Levothyroxine Sodium tablets are produced and marketed with around 12 varying potencies. Digoxin tablets are produced and marketed with approximately two different potencies. It distributes around three products containing Butalbital. Ursodiol capsules are produced and marketed in 300 milligram capsules. The Company offers a range of pain management products, such as Cocaine Topical Solution (C-Topical), Morphine Sulfate Oral Solution, Hydromorphone hydrochloric acid (HCl) tablets and Codeine Sulfate tablets.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: LCI
  • CUSIP: 51601210
Key Metrics:
  • Previous Close: $30.67
  • 50 Day Moving Average: $25.78
  • 200 Day Moving Average: $24.15
  • P/E Ratio: 15.27
  • P/E Growth: 0.45
  • Market Cap: $1.13B
  • Beta: 1.81
  • Current Year EPS Consensus Estimate: $3.27 EPS
  • Next Year EPS Consensus Estimate: $3.38 EPS
Additional Links:
Lannett (NYSE:LCI) Chart for Sunday, July, 24, 2016